Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.
“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J.